TUESDAY, June 24, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 study. Patients with moderate-to-severe bullous pemphigoid were randomly assigned to receive Dupixent 300 mg (53 individuals) or […]
The post FDA Approves Dupixent for Bullous Pemphigoid first appeared on Physician’s Weekly.
